New drug aims to stop skin lymphoma from returning after transplant

NCT ID NCT07178457

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether the drug brentuximab vedotin can prevent relapse in people with advanced cutaneous T-cell lymphoma (CTCL) who have recently had a stem cell transplant. About 84 adults with CD30-positive CTCL will receive either the drug or a placebo every three weeks for up to 16 cycles. The goal is to see if early treatment improves progression-free survival compared to waiting until the cancer returns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin
What this could lead to: If successful, this could offer a way to keep advanced CTCL from coming back after a stem cell transplant, potentially extending remission.
What could go wrong: This is a phase 3 trial, but it is not yet recruiting. The drug may cause side effects, and it is unclear if it will improve survival compared to waiting until relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRENTUXIMAB VEDOTIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRENTUXIMAB VEDOTIN CUTANEOUS T CELL LYMPHOMA (CTCL)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.